Allarity Therapeutics, Inc.
Data quality: 83%
ALLR
Nasdaq
Manufacturing
Chemicals
$1.16
▼
$0.01
(-0.43%)
Mkt Cap: 18.27 M
Price
$1.16
Mkt Cap
18.27 M
Day Range
$1.13 — $1.18
52-Week Range
$0.62 — $2.35
Volume
41,115
Open $1.17
50D / 200D Avg
$1.05
9.56% above
50D / 200D Avg
$1.19
3.23% below
Quick Summary
Key Takeaways
Negative free cash flow of -14.83 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-92.90%
Below sector avg (-53.41%)
ROIC-82.37%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio2.33
Interest Coverage-68.14
Valuation
PE (TTM)
-1.63
Below sector avg (-1.48)
P/B Ratio1.52
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -1.6 | -1.5 |
| P/B | 1.5 | 1.6 |
| ROE % | -92.9 | -53.4 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -11.23 M |
| ROE | -92.90% | ROA | -53.48% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -14.83 M |
| ROIC | -82.37% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 2.33 |
| Interest Coverage | -68.14 | Asset Turnover | N/A |
| Working Capital | 11.68 M | Tangible Book Value | 12.01 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1.63 | Forward P/E | N/A |
| P/B Ratio | 1.52 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -81.16% | ||
| Market Cap | 18.27 M | Enterprise Value | 1.38 M |
| Per Share | |||
| EPS (Diluted TTM) | N/A | Revenue / Share | N/A |
| FCF / Share | -0.94 | OCF / Share | -0.94 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 132.03% |
| SBC-Adj. FCF | -15.28 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -11.23 M | -24.52 M | -11.90 M | -16.06 M | -26.65 M |
| EPS (Diluted) | — | — | -10.26 | -2.21 | — |
| Gross Profit | — | — | -2.27 M | — | — |
| Operating Income | -12.61 M | -27.24 M | -17.13 M | -34.46 M | -26.56 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 6.60 M | 6.10 M | 7.10 M | 6.93 M | 14.20 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | 9,000.0 | 37,000.0 | 60,000.0 | 106,000.0 |
| Interest Expense | 185,000.0 | 653,000.0 | 498,000.0 | 12,000.0 | 93,000.0 |
| Income Tax | 0.0 | -381,000.0 | 83,000.0 | -1.52 M | 133,000.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 18.26 M | 22.65 M | 11.86 M | 14.54 M | 49.63 M |
| Total Liabilities | 8.43 M | 10.84 M | 14.61 M | 12.65 M | 30.85 M |
| Shareholders' Equity | 9.83 M | 11.81 M | -2.75 M | -113,000.0 | 18.15 M |
| Total Debt | — | 2.69 M | — | 2.64 M | — |
| Cash & Equivalents | 14.69 M | 19.53 M | 166,000.0 | — | — |
| Current Assets | 17.93 M | 22.34 M | 1.97 M | 4.97 M | 21.05 M |
| Current Liabilities | 8.43 M | 10.84 M | 14.17 M | 11.22 M | 20.72 M |
{"event":"ticker_viewed","properties":{"ticker":"ALLR","listing_kind":"stock","pathname":"/stocks/allr","exchange":"Nasdaq","country":"US"}}